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Subthreshold depression as a risk indicator
for major depressive disorder: a systematic
review of prospective studies
Introduction
Subthreshold depression (sD) has been found to
be a highly prevalent condition (1, 2), with a
considerable impact on the quality of life of
patients (3–5), resulting in a strongly increased
service utilization (6), and it has been found to
be associated with large-scale economic costs
because of disability days (7). A person can be
considered to have sD when he or she has
clinically relevant depressive symptoms, without
meeting criteria for a full-blown major depressive
disorder (MDD). The clinically relevant depres-
sive symptoms in sD can either be operational-
ized as scoring above a cut-oﬀ score on a self-
rating depression scale, as having a depressed
mood with one or more additional symptoms of
a mood disorder, or as meeting the criteria of
minor depression (mD), as deﬁned in the Appen-
dix of the DSM-IV.
The sD can be considered as a signiﬁcant risk-
indicator of MDD because it can be regarded as a
part of the prodomal phase of MDD (8). All or
nearly all subjects who develop MDD can be
assumed to have initially passed through a period
(however, brief) of sD. On the contrary, not all
subjects with sD will eventually develop MDD.
Assessing the incidence of MDD in patients
exhibiting sD is important for several reasons.
First, it is an important indicator for the clinical
relevance of sD. Secondly, it is important for
understanding the process by which an individual
develops MDD and the role of depressive symp-
toms in the process. Thirdly, the increased risk is
important because it may provide a rationale for
the development of new interventions that prevent
the onset of new cases of MDD. Several recent
studies in this area have found evidence that it is
indeed possible to reduce the number of new cases
of MDD by intervening in subjects with sD (9–11).
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Objective: In order to examine whether the incidence of major
depressive disorder (MDD) is increased in subjects with subthreshold
depression, or sD (clinically relevant depressive symptoms, without
meeting criteria for a full-blown MDD), we conducted a review of
prospective studies examining the incidence of MDD in subjects with
sD.
Method: A systematic literature search was conducted. For all studies,
the relative risk of developing MDD was calculated, based on person-
years.
Results: Twenty studies (23 comparisons) were found, based on
community samples, general medical patients and high-risk subjects.
Most comparisons showed that subjects with sD had a consistently
larger chance of developing MDD. The studies diﬀered considerably in
the deﬁnition of sD, the recency (occurrence of the last sD) and the in-/
exclusion of lifetime MDD.
Conclusion: The incidence of MDD in subjects with sD is larger than
in subjects without sD. Otherwise, the concept of sD is too broad to be
used. In future studies, some consensus should be reached regarding
the deﬁnition of sD.
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Aims of the study
In this study, we conduct a systematic review of
prospective studies examining the incidence of
MDD in subjects with sD. We examine if the
research in this area conﬁrms the presupposition
that subjects with sD have a greater probability of
getting MDD than subjects without sD. We also
examine how large the incidence rate is in sD, and
whether the increased incidence rates are compar-
able for the diﬀering studies.
Material and methods
Selection of studies
Studies were traced through several computerized
literature databases (Medline, 1966–April 2002;
Psychinfo, 1960–April 2002), by combining key
words indicating sD (minor, subclinical), depres-
sion (MeSH and textword, depressi*) and the
prospective character of the study (MeSH terms
and textwords-like prospective, incidence, follow-
up, epidemiology, cohort). In the computerized
databases abstracts were read and papers which
possibly met inclusion criteria were collected.
Reference lists of retrieved papers were screened,
and papers that possibly met inclusion criteria were
retrieved and studied. Furthermore, references
from major reviews in this area were examined
(12–15).
In order to be included in the review, the study
had to be prospective with at least two measure-
ment points, and it had to include subjects meeting
one of the deﬁnitions of sD. Furthermore, it was
required that the presence of MDD was excluded
at the ﬁrst measurement by using a diagnostic
interview [such as the Composite International
Diagnostic Interview, CIDI (16) the Schedule for
Clinical Assessment in Neuropsychiatry SCAN
(17), or the Diagnostic Interview Schedule, DIS
(18)], and it was required that a comparison group
of subjects without sD and without MDD at the
ﬁrst measurement point was included. We did not
include studies of patient groups who were treated
for mental problems, as we assumed that the
treatment would inﬂuence the incidence rates. sD
could be deﬁned as either meeting criteria for mD
(as deﬁned in the DSM-IV, the ICD-10 or the
Research Diagnostic Criteria), having mood prob-
lems, or scoring above a cut-oﬀ point on a
self-rating depression inventory, but below the
threshold of full-blown MDD. We also included
studies examining brief recurrent depression as this
can also be considered to be a subthreshold
condition for MDD (19).
Analyses
Follow-up period. Because the follow-up period of
the studies diﬀered considerably, we based the
calculation of the incidence rates on person-years.
That is, we divided the number of new MMD cases
that occurred in the time period (the numerator) by
the total amount of person-time units (person-
years) of the group at risk (the denominator).
Technically, this is known as the person-time
incidence rate, or the incidence density rate. The
person-time incidence rate is an appropriate meas-
ure of incidence when follow-up times are unequal
(16).
Statistics. For each study we calculated the inci-
dence rate ratio (IRR) which has the same inter-
pretation as the more commonly known relative
risk (RR), or its approximate, the odds ratio (OR).
Results
Included studies
A total of 43 198 subjects were examined in the 20
studies that met inclusion criteria, including 6049
subjects with sD. In three studies, two categories of
sD with diﬀerent deﬁnitions were examined (1, 20,
21). Therefore, the total number of comparisons
between a group of subjects with sD with a control
group was 23.
Three groups of studies could be distinguished
(one study consisted of two separate samples that
were categorized into two of the three following
groups of studies): (i) studies examining commu-
nity samples (10 studies with 13 samples, and with
a total of 41 041subjects, including 5573 subjects
with sD) (1, 2, 7, 8, 19, 20, 22–25, 28); (ii) studies of
general medical patients (seven studies with seven
samples; 1067 subjects, 268 with sD) (6, 26–31); (iii)
studies of high-risk groups (three studies with three
samples; 1090 subjects, 208 with sD) (28, 32, 33).
Selected characteristics of these three groups of
studies are presented in Table 1.
The studies diﬀered on several characteristics,
including the operationalization of sD, the length
of the follow-up period, the composition of the
comparison group and the measures of MDD
(Table 1).
Overall outcomes
The RRs are reported in Table 2 for each of the
comparisons in the studies. In 16 of the 23 com-
parisons a signiﬁcantly increased RR of developing
MDD was found for subjects with sD (11 of 13
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comparisons from community studies; three of
seven comparisons from medical patient studies;
and two of three comparisons from the high-risk
studies). Four of seven other comparisons also
indicated an increased RR of developing MDD,
although these did not reach signiﬁcance levels.
The three remaining comparisons did not indicate
an increased RR, but none of the resulting RRs
(indicating a decreased risk of developing MDD)
was signiﬁcant, and two of three examined subjects
who for a large part had considerable cognitive
dysfunction (26, 29).
Although the direction of the outcomes was
conﬁrmed by nearly all studies, the heterogeneity
of the studies was very large. In the general
population studies, the incidence density rates in
subjects with sD ranged from 0.01 to 0.15 new
cases per 100 person years, compared with 0.00–
0.05 in subjects without sD. In general medical
patients, the incidence density rates in subjects with
sD ranged from 0.06–0.58 to 0.00–0.23 in subjects
without sD. In the high-risk groups, the incidence
density rates were 0.02–0.27 for subjects with sD,
and 0.01–0.07 for subjects without sD.
The RRs in the general population studies varied
from 1.15 to as much as 9.73 (in one study even
much higher RRs were found, but these were based
on very small samples and can be considered to be
an outlier) (20). In the general medical patients, the
RRs varied from 0.53 to 5.14 and in the high-risk
groups from 2.56 to 6.18.
Operationalization of sD
Although considerable heterogeneity could be
expected because of the diﬀerences in study
designs, we examined potential sources of hetero-
geneity across studies. We found that especially the
operationalizations of sD diﬀered considerably in
the 20 studies. We found that the diﬀerences
mainly occurred along three important dimensions.
1 Deﬁnition: Four deﬁnitions of sD could be
distinguished: (i) mD according to DSM-IV
criteria, or a similar deﬁnition; (ii) mood
problems with one other symptom, but not
more; (iii) mood problems, with or without
other symptoms; (iv) other deﬁnitions (e.g. a
high score on a self-rating scale; and combi-
nations of recurrent brief depression and other
deﬁnitions of sD).
2 Recency: The period during which sD had
been present before the ﬁrst measurement
varied. We distinguished three periods: (i)
current; (ii) last year; (iii) lifetime. It was
assumed that the prevalence of lifetime sD was
Table 2. Prospective studies of developing major depression in subjects with subthreshold depression: relative risks and incidence density rates
LT MDD excl Recency of sD Study IncsD Incctr RR 95% CI
Community studies
Minor depression Yes Past year Eaton 0.083 0.015 5.72 1.54–14.97
Cuijpers A 0.035 0.008 4.59 2.76–7.52
Lifetime Chen 0.015 0.003 5.91 3.48–9.76
Bruce 0.020 0.017 1.15 0.52–2.31
No Current Judd A 0.055 0.000 340.23 41.27–15651.82
One symptom only Yes Past year Cuijpers B 0.018 0.008 2.36 0.90–5.30
No Current Judd B + C 0.006 0.000 39.35 5.06–1774.27
At least one symptom Yes Lifetime Horwarth 0.034 0.008 4.43 3.12–6.32
No Past year Broadhead 0.108 0.011 9.73 4.92–19.00
Other definitions Angst 0.023 0.013 1.81 1.11–2.90
Gotlib 0.149 0.053 2.80 1.90–4.07
Oldehinkel 0.122 0.030 4.09 1.99–7.77
Maier 96B 0.049 0.008 5.91 2.49–14.16
Medical patients
Minor depression No Current Parmelee 0.176 0.058 3.04 1.34–6.67
Wagner 0.220 0.000 3.41*
Schleifer 0.583 0.227 2.57 0.70–10.26
Ballard 0.100 0.114 0.88 0.084–5.37
Maier 0.190 0.037 5.14 1.10–20.23
Starkstein 0.111 0.000 0.57*
Morris 0.063 0.118 0.53 0.010–5.37
High-risk groups
Minor depression Yes Current Warner 0.182 0.029 6.18 1.28–26.07
Lifetime Maier 96A 0.016 0.006 2.56 0.253–14.32
No Current Brown 0.273 0.067 4.05 1.28–11.22
*No 95% confidence intervals reported because the incidence in the control group was zero.
LT MDD excl, lifetime MDD excluded yes/no; IncsD, incidence density rate in subjects with sD; Incctr, incidence density rate in control subjects; RR, relative risk; sD,
subthreshold depression.
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considerably larger than last year or current
sD, but that the risk of getting MDD was
larger in current sD.
3 In-/exclusion of lifetime MDD: As MDD is in
many cases a recurrent or even chronic disor-
der, it was assumed that inclusion of lifetime
MDD would result in a higher incidence rate
of MDD for subjects with sD, reﬂecting the
distinction between ﬁrst-ever incidence and
repeat incidence of MDD.
Using these three dimensions and the three
groups of target populations, 72 ways (4*3*2*3)
to operationalize sD were found to be possible.
The 20 included studies covered 11 of these
categories (Table 2). Only one of the categories
consisted of more than two studies (current mD in
general medical patients, no exclusion of lifetime
MDD).
Further analyses
Given the considerable heterogeneity of included
studies, a meta-analysis of the whole sample of
studies was not feasible.
Discussion
We conducted a large review on a clinically
important topic using rigorous inclusion and
exclusion criteria. But this study also has several
limitations. First, the number of studies examining
the incidence of MDD in subjects with sD is
relatively small, compared with the large varia-
tions in operationalizing sD. Apart from the
diﬀerences in operationalization, several other
diﬀerences existed between study designs, meas-
urement instruments and populations. These large
diﬀerences across studies made it impossible to
conduct a meta-analysis. Another important limi-
tation of this study is that we, because of the
diﬀerences in follow-up periods, calculated the
number of new cases over the total follow-up
period, assuming that the new cases were evenly
distributed over the follow-up period. This does
not have to be the case, of course, and this could
have distorted the outcomes. Because of these
limitations, the results of this study should be
considered with caution.
On the contrary, it is remarkable that in spite of
the large amount of heterogeneity across studies, a
fairly consistent pattern was found indicating a
seriously increased incidence of MDD in sD
compared to subjects without sD. Only very few
studies did not support this conclusion. However,
the studies included in this review do not allow us
to determine exactly how much the incidence rate is
increased by established sD. The heterogeneity of
the set of studies is unsettling and the incidence
rates diﬀer dramatically between studies. The
incidence rates probably depend heavily on the
operationalization of sD. The varying deﬁnitions
of sD, the diﬀerences in how long ago the sD was
present in the subjects (current, last year, lifetime),
the type and size of case and control samples,
length of follow-up, and the in- or exclusion of
subjects with a lifetime MDD, are probably very
important characteristics of the studies, rendering
them incomparable.
Because of the many deﬁnitions and operation-
alizations, the concept of sD is not useful in
research or in practice. It can be safely assumed
that the incidence of MDD in subjects with sD is
larger than in subjects without sD, but how much
of them will actually get MDD depends heavily on
the deﬁnition.
It is crucial for future studies to reach some
agreement on deﬁnitions and operationalizations
of sD when examining the incidence of MDD in
subjects with sD. From a clinical point of view, it
would be most important to examine subjects with
current sD, as these present themselves often in
general or specialized general medical practices and
can therefore be better identiﬁed than subjects with
last-year or lifetime sD. Because mD has now been
deﬁned in the DSM-IV and a growing number of
studies has used these criteria, it would be useful to
apply this deﬁnition of sD in future studies.
The incidence rates of MDD in sD diﬀered very
much between studies. In general population stud-
ies, the incidence rates seemed to be smaller (not
exceeding 0.15), while in general medical popula-
tions and in high-risk groups the incidence rates
were higher (up to 0.58). Trials examining the
eﬀects of preventive interventions on the incidence
of MDD in sD should concentrate on the general
medical populations and the high-risk groups, as
low incidence rates result in statistical power
problems in preventive trials (34). This means
that very large sample sizes are required to be able
to show a reduction of this incidence rate.
It would be useful to improve the identiﬁcation
of subjects with sD who will develop MDD. One
possibility for this would be to identity the pres-
ence of sD in subjects belonging to high-risk
groups. For example, a recent study examining a
preventive intervention focused on subjects who
not only had sD, but also belonged to another
high-risk group (adolescent children of depressed
parents) (10). Such combinations of risk factors
may well constitute the basis for a new generation
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of preventive trials. Studies of these high-risk
groups (and a corresponding high-incidence rate)
need to include less subjects in order to get
suﬃcient statistical power, and are therefore also
of scientiﬁc interest (34).
The present review conﬁrms that, although the
concept of sD has to be deﬁned more precisely, sD
should be considered as a signiﬁcant health prob-
lem, as it strongly predicts later onset of MDD.
From this point of view, it is important to clarify
and standardize the concept of sD, as was done
with mD in the DSM-IV, and to continue devel-
oping preventive interventions aimed at the pre-
vention of MDD and the treatment of clinically
relevant forms of sD.
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